“After more than a year of carefully considering potential buyers for my company, I ultimately chose Prairie over several competing investment firms to acquire Cantor BioConnect. Throughout the process, Prairie demonstrated exceptional professionalism and established itself as a trusted leader and partner in the industry. I am extremely pleased with my decision to partner with Prairie and confident they will take Cantor BioConnect to the next level.”
Biospecimen Holdings
Prairie Capital Fund VII
Provider of biospecimens and CRO services to global biopharma and diagnostic customers through a consortium of companies
David Cantor
Founder, Cantor BioConnect

